Agile Therapeutics Announces Proposed Offering of Common Stock
22 1월 2016 - 6:05AM
Agile Therapeutics, Inc. (Nasdaq:AGRX), a women’s health specialty
pharmaceutical company focused on the development and
commercialization of new prescription contraceptive products, today
announced that it intends to offer and sell $30 million of shares
of its common stock, subject to market and other conditions, in an
underwritten public offering. Agile Therapeutics intends to grant
the underwriters a 30-day option to purchase up to $4.5 million of
additional shares of common stock.
The joint book-running managers for the offering
are William Blair and RBC Capital Markets. In
addition, Janney Montgomery Scott, Cantor Fitzgerald & Co., and
FBR are acting as co-managers.
The shares of common stock described above are
being offered by Agile Therapeutics pursuant to its shelf
registration statement on Form S-3 previously filed and declared
effective by the Securities and Exchange Commission. The
offering is being made only by means of a preliminary prospectus
supplement and the accompanying prospectus, copies of which may be
obtained, when available, from William Blair & Company, L.L.C.,
Attention: Prospectus Department, 222 West Adams
Street, Chicago, IL 60606; Telephone: (800) 621-0687 or
by email at prospectus@williamblair.com and RBC Capital
Markets, LLC, 200 Vesey Street, 8th Floor, New York,
NY 10281-8098; Attention: Equity Syndicate; Tel: (877)
822-4089; email: equityprospectus@rbccm.com.
This press release shall not constitute an offer
to sell or a solicitation of an offer to buy these securities, nor
shall there be any sale of these securities in any state or
jurisdiction in which such offer, solicitation or sale would be
unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Agile Therapeutics, Inc.Agile
Therapeutics is a women's health specialty pharmaceutical company
focused on the development and commercialization of new
prescription contraceptive products. Our product candidates are
designed to provide women with contraceptive options that offer
greater convenience and facilitate compliance. Our lead product
candidate, Twirla®, (ethinyl estradiol and levonorgestrel
transdermal system), also known as AG200-15, is a once-weekly
prescription contraceptive patch currently in Phase 3 clinical
development. Twirla is based on our proprietary transdermal patch
technology, called Skinfusion®, which is designed to provide
advantages over currently available patches and is intended to
optimize patch adherence and patient acceptability.
Forward-Looking Statement
Certain information contained in this press
release includes "forward-looking statements" within the meaning of
The Private Securities Litigation Reform Act of 1995, including
statements related to our public offering and potential market
opportunity for our product candidates. We may, in some cases use
terms such as "predicts," "believes," "potential," "continue,"
"anticipates", "estimates," "expects," "plans," "intends," "may,"
"could," 'might," "will," "should" or other words that convey
uncertainty of the future events or outcomes to identify these
forward-looking statements. Our forward-looking statements are
based on current expectations that involve risks, potential changes
in circumstances, assumptions and uncertainties. Any or all of the
forward-looking statements may turn out to be wrong, or be affected
by inaccurate assumptions we might make or by known or unknown
risks and uncertainties as a result of various important factors,
including the uncertainties related to market conditions and the
completion of the public offering on the anticipated terms or at
all and such other factors. For a further description of the
risks and uncertainties that could cause actual results to differ
from those expressed in these forward-looking statements, as well
as risks relating to our business in general, please refer to our
prospectus supplement to be filed with the Securities and Exchange
Commission (SEC) on January 21, 2016 under the heading “Risk
Factors” and those documents incorporated by reference therein,
which includes our Quarterly Report on Form 10-Q filed with the SEC
on November 9, 2015. You are cautioned not to place undue reliance
on these forward-looking statements, which are made only as of the
date of this press release. We undertake no obligation to publicly
update such forward-looking statements to reflect subsequent events
or circumstances.
Contact: Mary Coleman -- 609-356-1921
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 6월(6) 2024 으로 7월(7) 2024
Agile Therapeutics (NASDAQ:AGRX)
과거 데이터 주식 차트
부터 7월(7) 2023 으로 7월(7) 2024